RxDoctor Payments Data

Dali Feng, MD

Cardiovascular Disease · Minneapolis, MNNPI 1215917646

Payments from drug & device makers

$2,525in general payments, 2019–2025

Across 41 payments — averaging $61.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$986
  • Edwards Lifesciences$589
  • Heartflow, Inc.$186
  • Abbott$176
  • Boston Scientific$148
  • GE HealthCare$117
  • plus $323 from 5 others

What the payments were for

  • Grants$894%
  • Travel & lodging$71828%
  • Food & beverage$1,71868%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,525 in reported general payments places this provider in the 50th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$62,087
Medicare patients
550
Services billed
1,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$128,033
XareltoRivaroxaban75$93,911
JardianceEmpagliflozin36$46,695
EntrestoSacubitril/Valsartan24$29,291
Atorvastatin Calcium378$4,974
Metoprolol Succinate213$4,180
Ezetimibe151$3,257
Rosuvastatin Calcium130$1,767
Amlodipine Besylate159$1,723
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$1,053
Lisinopril95$952
Losartan Potassium82$915
Metoprolol Tartrate62$812
Isosorbide Mononitrate ErIsosorbide Mononitrate49$810
Hydralazine Hcl39$808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$16$29,29124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →